JPMorgan reiterates Overweight rating on argenx stock after positive trial

Argenx SE (NASDAQ:ARGX) reported exceptional Q2 2025 earnings, with EPS of $6.32 and revenue of $1.74 billion, significantly exceeding market expectations by over 100% and 98% respectively. Concurrently, its key drug Vyvgart achieved positive headline results in the ADAPT SERON trial for seronegative generalized Myasthenia Gravis patients, demonstrating statistically significant and clinically meaningful improvement, which is expected to broaden its label and enhance its competitive profile. These robust financial and clinical advancements have prompted JPMorgan, Oppenheimer, and RBC Capital to reiterate or initiate Outperform/Overweight ratings with strong price targets, underscoring the company's strong growth trajectory and product potential.

Analysis

Argenx SE (ARGX) has delivered a powerful combination of exceptional financial performance and a significant clinical trial success, reinforcing its growth narrative. The company reported blowout Q2 2025 results, with revenue of $1.74 billion and EPS of $6.32 exceeding consensus estimates by 98.56% and 106.54% respectively, signaling robust commercial execution and demand for its products. This financial outperformance is complemented by positive headline results from the ADAPT SERON Phase 3 trial for its key drug, Vyvgart, in seronegative generalized Myasthenia Gravis (gMG) patients. The trial met its primary endpoint with statistically significant and clinically meaningful improvement, a critical development that is expected to broaden Vyvgart's label and strengthen its competitive moat. This dual catalyst has prompted strong endorsements from the analyst community, with JPMorgan, Oppenheimer, and RBC Capital all reiterating Outperform/Overweight ratings and issuing high price targets ranging from $778 to $850, underscoring conviction in the company's trajectory.

Key Decisions for Investors

• Given the significant earnings beat and positive Phase 3 data de-risking a key asset, investors may view this as a strong validation of the company's growth thesis and a potential opportunity to initiate or increase positions.
• Attention should now turn to the execution of the Vyvgart label expansion; investors should monitor regulatory submission timelines and subsequent commercial uptake in the newly approved patient population.
• While the outlook is overwhelmingly positive, it is prudent to assess the stock's valuation following these developments and consider if the substantial upside implied by analyst price targets is already partially priced in.